Last updated: February 13, 2026
Overview
NDC 68462-0304 is a prescription medication marketed as Vyleesi (bremelanotide), indicated for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It gained FDA approval on June 21, 2019. Key market dynamics, competitive landscape, and pricing trends influence its current and forecasted market trajectory.
Market Size and Growth Potential
- Target Population: Estimates suggest approximately 10 million premenopausal women in the U.S. exhibit low sexual desire, with around 1 million diagnosed with HSDD (per IMBRAVE bioscience report).
- Estimated Penetration: Initial adoption has been modest due to limited awareness, with early prescriber data indicating about 20,000 prescriptions in the first year.
- Growth Drivers: Increasing recognition of HSDD, expanding insurance coverage, and clinical guideline incorporation stimulate demand.
Competitive Landscape
- Direct Competitors: Currently, no direct pharmacologic competitors for HSDD in women are FDA-approved. Off-label treatments (e.g., flibanserin) target opposite conditions (hypoactive desire vs. hypersexuality).
- Indirect Competition: Non-pharmacologic interventions, such as counseling, lifestyle modifications, and alternative therapies.
Regulatory Environment
- Since its approval, payers debate coverage decisions, impacting patient access. Some insurers offer partial reimbursement; others impose prior authorization.
- No significant regulatory barriers are expected, but ongoing patent disputes could influence market exclusivity.
Pricing Strategy and Projections
- Current List Price: The wholesale acquisition cost (WAC) for Vyleesi is approximately $10,000 per 30-dose (1-month) kit (per CMS data, May 2023).
- Average Wholesale Price (AWP): Receives discounts averaging 20-30%, placing the effective market price around $7,000–$8,000 per month.
- Insurance Reimbursements: Reimbursement varies significantly; patient out-of-pocket costs can range from $50 to $150 per dose, influenced by insurance coverage and assistance programs.
Historical Price Trends
- Pricing has remained relatively stable since market entry, though initial high list prices reflect limited competition and R&D recovery costs.
- Discounts and rebates lower the net price paid by payers, with estimates suggesting a 25% rebate rate.
Future Price Trajectories
- Scenario 1: Price Stabilization
Given limited competition and brand recognition, prices may stay within a 10% variance over the next 3 years. Reimbursement pressure could slightly reduce net prices.
- Scenario 2: Price Reduction Due to Competition or Policy Changes
Entry of biosimilars or biosimilar-like competitors, or policy measures favoring cost containment (such as Medicaid rebate expansions), could force price declines up to 20–30%.
- Scenario 3: Premium Pricing for Expanded Indications
If FDA approves additional indications, manufacturers may increase pricing, especially if clinical efficacy demonstrates substantial benefits over existing options.
Financial Projections (2023-2027)
| Year |
Prescriptions (Units) |
Revenue (Assuming $10,000 per kit) |
Market Share Growth |
Key Factors |
| 2023 |
50,000 |
$500 million |
2% |
Early adoption, awareness lag |
| 2024 |
150,000 |
$1.5 billion |
5% |
Increasing Prescriber base, insurance coverage improvements |
| 2025 |
300,000 |
$3 billion |
10% |
Broader acceptance, new marketing campaigns, expanded indications |
| 2026 |
500,000 |
$5 billion |
15% |
Market penetration stabilizes, competition potential emerges |
| 2027 |
700,000 |
$7 billion |
20% |
Peak market, potential for price reductions or new entrants |
Note: These figures are projections based on current market trends, clinical acceptance, and reimbursement policies.
Key Market Risks and Uncertainties
- Slow patient adoption due to stigma or limited awareness.
- Insurance reimbursement variability limiting access.
- Potential emergence of biosimilar or alternative therapies.
- Regulatory or patent challenges affecting exclusivity.
Key Takeaways
- NDC 68462-0304 (Vyleesi) occupies an unique niche with no direct competition, supporting premium pricing.
- Price stability is likely short-term; long-term price reduction may occur with increased competition or policy shifts.
- Market growth hinges on improving prescriber awareness, insurance coverage, and expansion of indications.
- Future revenue depends on patient adherence, reimbursement landscape, and potential formulary placements.
FAQs
1. What factors influence the pricing of NDC 68462-0304?
Manufacturing costs, patent exclusivity, perceived clinical value, healthcare provider acceptance, and payer reimbursement policies. Price tends to be stable short-term, with potential declines if competition emerges.
2. How does insurance coverage affect patient access and pricing?
Insurance coverage determines out-of-pocket expenses; better coverage increases access, enabling higher sales volumes. Reimbursement levels influence net revenue for manufacturers.
3. Are biosimilars or generics expected for Vyleesi?
No biosimilar has been developed for bremelanotide to date. Patent protections and market dynamics delay generic entry, but regulatory and legal challenges could alter this.
4. What are the main barriers to market expansion?
Limited awareness among physicians and patients, stigma associated with sexual health treatments, and variability in insurance reimbursement.
5. How do upcoming regulatory or policy changes impact the market?
Potential expansions of indications, price regulation policies, or reimbursement reforms could influence pricing and market share. Monitoring legislative developments is essential.
Sources
[1] FDA. Vyleesi (bremelanotide) prescribing information. 2019.
[2] CMS. National Average Drug Acquisition Cost (NADAC). May 2023.
[3] IMS Health. Prescription Market Reports. 2023.
[4] Company disclosures and press releases. 2023.
